Nature of the Disclosure

This is a notice for a postal ballot, filed with BSE Limited, seeking shareholder approval for the appointment of a director, as required under the Companies Act, 2013 and SEBI Listing Regulations.

Key Resolution

Ordinary Resolution: Appointment/Continuation of Mr. Saahil Parikh (DIN: 00400079) as a Non-Executive, Non-Independent Director of Makers Laboratories Limited, liable to retire by rotation, effective from August 11, 2026.

Dates and Timeline

  • Notice Date: September 10, 2026 (Letter to BSE); August 7, 2026 (Postal Ballot Notice)
  • Dispatch Date: The postal ballot notice is being dispatched on Tuesday, September 15, 2026.
  • Cut-off Date: Friday, September 11, 2026 (for determining shareholders eligible to vote).
  • E-Voting Period: Commences at 9:00 AM IST on Thursday, September 17, 2026, and concludes at 5:00 PM IST on Friday, October 16, 2026.
  • Deemed Date of Passing: If passed, the resolution will be deemed to have been passed on Friday, October 16, 2026.
  • Result Declaration: The results will be announced within 2 working days from the conclusion of e-voting.

Parties Involved

  • Stock Exchange: BSE Limited
  • Director in Question: Mr. Saahil Parikh (DIN: 00400079)
  • Scrutinizer: Ms. Jigyasa N. Ved (Membership No. FCS6488 CP6018), with Mr. P. N. Parikh (FCS327 CP1228) and Mr. Mitesh Dhabliwala (FCS8331 CP9511) as substitutes.
  • E-Voting Service Provider: National Securities Depository Limited (NSDL)
  • Company Secretary: Piyush Ajmera (ACS 58712)

Details of the Proposed Director - Mr. Saahil Parikh

  • Age: 51 years (Date of Birth: January 27, 1975)
  • Qualifications: B.Sc in Bio-Chemistry from Gujarat University; Diploma in Management Studies from Ahmedabad Management Association.
  • Expertise: Research & Development, Technical, Manufacturing & Marketing, Commercial, Regulatory, Finance, Legal & General Management.
  • Previous Role: Whole-time Director/CEO of the company from August 11, 2011, until August 10, 2026.
  • Reason for Change: He decided not to continue as Whole-time Director/CEO due to personal and professional reasons but agreed to continue as a Non-Executive Director.
  • Experience: Approximately 25 years in Pharma Production, Quality Control, Projects, and General Management.
  • Remuneration: As Whole-time Director, he last drew remuneration of ₹73.34 lakh. In his new Non-Executive role, he will only be paid sitting fees for attending Board and Committee meetings.
  • Shareholding: Holds 21,741 equity shares in the company.
  • Other Directorships: Holds no directorships in any other companies.
  • Board Attendance: Attended 5 out of 5 board meetings held in FY 2025-26.
  • Committee Membership: He is a member of the Stakeholders Relationship Committee of the company.
  • Eligibility: He is not debarred from holding the office of Director by any SEBI or other competent authority order.

Voting Procedure

  • The voting is to be conducted entirely through remote e-voting via the NSDL platform (evoting.nsdl.com).
  • Physical ballot forms are not being sent.
  • The notice is being sent electronically to all members whose email addresses are registered with the company/depository participants.
  • Detailed instructions for shareholders holding shares in both demat and physical form are provided for accessing the e-voting system.

Financial and Operational Impact

The appointment is a change in management structure but has no direct quantified financial impact on the company beyond the payment of sitting fees, which is standard for non-executive directors. The disclosure states his experience will be of "immense benefit" to the company.

#Tags: #MakersLaboratories #DirectorAppointment #PostalBallot #SEBIDisclosure #CorporateGovernance #Neutral